Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 891 of 5804
-
New drug VHB937 aims to slow ALS progression in Early-Stage patients
Disease control OngoingThis is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treat…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New gene therapy aims to tackle fabry disease in early trial
Disease control Recruiting nowObjective: To explore the safety and tolerability of different doses of EXG110 with Fabre disease
Phase: NA • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Placental grafts show promise for stubborn ulcers
Disease control CompletedThe purpose of this study is to determine how well multiple CAMPs (Cellular, Acellular and Matrix-Like Products) and Standard of Care work when compared to Standard of Care alone in achieving complete closure of diabetic foot and venous leg ulcers.
Phase: PHASE4 • Sponsor: Cellution Biologics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo aims to tame ulcerative colitis
Disease control Recruiting nowThe main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo therapy aims to fight hard-to-treat lymphoma
Disease control Recruiting nowSingle-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphoma including patients with Adult T…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New shot aims to cut migraine days in half
Disease control Recruiting nowThe purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Tailored surgery may help kids with sleep apnea and small tonsils
Disease control Recruiting nowThe purpose of this study is to compare the effectiveness of a novel personalized surgical approach to the standard AT in children with small tonsils (ST). This will be accomplished by randomizing children with ST and OSA to one of these two treatments and comparing outcomes afte…
Phase: NA • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Can a $10 arthritis pill tame rare blood cancers?
Disease control Recruiting nowLow-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was identified as a type 2 JAK inhibitor. If MTX proves to be safe and tolerable with a signal of clinical activity, this coul…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Heart attack diagnosis revolution? new method could save lives
Diagnosis OngoingThe investigators hypothesize that occlusion myocardial infarction(MI)/non-occlusion MI approach to MI treatment will better predict acute coronary occlusion on coronary angiography, better limit infarct size, better preserve left ventricular function and result in lower long-ter…
Phase: NA • Sponsor: Başakşehir Çam & Sakura City Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 13:02 UTC
-
Blood test aims to unmask hidden TB infections before they turn deadly
Knowledge-focused ENROLLING_BY_INVITATIONMycobacterium tuberculosis (Mtb) is a major human pathogen, responsible for an estimated 10.6 million cases of active tuberculosis (TB) and 1.6 million deaths in 2021. Most adult cases of active TB arise from progression of latent tuberculosis infection (LTBI), whose global preva…
Sponsor: Queen Mary University of London • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Phase: PHASE2 • Sponsor: Huabo Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:58 UTC
-
New cholesterol drugs show promise in Late-Stage trial
Disease control CompletedA Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia
Phase: PHASE3 • Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Parkinson's psychosis drug shows promise in final trial
Symptom relief CompletedThe purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
Phase: PHASE3 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Pedaling past paralysis: cycling therapy shows promise for stroke survivors
Symptom relief Recruiting nowTraditional rehabilitation approaches are time and personnel intensive and costly, and leave \~75% of stroke survivors with residual disability. We propose a clinical trial to determine effects of forced aerobic exercise (FE; i.e., mechanically supplemented) in facilitating upper…
Phase: NA • Sponsor: The Cleveland Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
Could cochlear implants help more people hear? new study expands eligibility.
Symptom relief OngoingThis study aims to evaluate the safety and efficacy of cochlear implantation for adults with bilateral sensorineural hearing loss who currently do not meet the FDA-approved indications for cochlear implantation. Following cochlear implantation, participants will complete speech p…
Phase: NA • Sponsor: Cochlear • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowVET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumora…
Phase: PHASE1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a daily pill keep the weight off after stopping injectables?
Disease control CompletedThe main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT0…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control TerminatedThis is an open-label, investigator-initiated clinical trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with active SLE, SSc, AAV, IIM, and pSS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Cheaper keytruda clone tested for early lung cancer
Disease control OngoingThe primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New combo shot targets stomach cancer belly fluid
Disease control Recruiting nowThis study is to evaluate the safety and efficacy of intraperitoneal injection of immune checkpoint inhibitor combined with zoledronic acid for the treatment of malignant ascites in gastric cancer. This study is a phase Ib/II clinical study to evaluate the safety and efficacy of…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC